Pitfalls of Cost-Effectiveness Analysis in Practice: A TRD Case Example in the United States with Esketamine Versus Oral Antidepressants
Open Access
- 1 April 2020
- journal article
- letter
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 26 (4), 568-569
- https://doi.org/10.18553/jmcp.2020.26.4.568
Abstract
DISCLOSURES: The writing of this letter was supported by Janssen Scientific Affairs. The authors are employees of Janssen Scientific Affairs or Janssen Global Services (Johnson & Johnson).Keywords
This publication has 3 references indexed in Scilit:
- The Effectiveness and Value of Esketamine for the Management of Treatment-Resistant DepressionJournal of Managed Care & Specialty Pharmacy, 2020
- Nonpharmacologic Versus Pharmacologic Treatment of Adult Patients With Major Depressive Disorder: A Clinical Practice Guideline From the American College of PhysiciansAnnals of Internal Medicine, 2016
- Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D ReportAmerican Journal of Psychiatry, 2006